pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
=== Chemical synthesis === Droplet-based microfluidics has become an important tool in chemical synthesis due to several attractive features. Microscale reactions allow for cost reduction through the usage of small reagent volumes, rapid reactions in the order of milliseconds, and efficient heat transfer that leads to environmental benefits when the amount of energy consumed per unit temperature rise can be extremely small. The degree of control over local conditions within the devices often makes it possible to select one product over another with high precision. With high product selectivity and small sizes of reagents and reaction environments come less stringent reaction clean-up and smaller footprint. Microdispersed droplets created by droplet-based chemistry are capable of acting as environments in which chemical reactions occur, as reagent carriers in the process of generating complex nanostructures. Droplets are also capable of being transformed into cell-like structures which can be used to mimic humans' biological components and processes. As a method of chemical synthesis, Droplets in microfluidics devices act as individual reaction chambers protected from contamination through device fouling by the continuous phase. Benefits of synthesis using this regime (compared to batch processes) include high throughput, continuous experiments, low waste, portability, and a high degree of synthetic control. Some examples of possible syntheses are the creation of semiconductor microspheres and nanoparticles.
=== Cardiac conditions === Subtypes of troponin (cardiac I and T) are sensitive and specific indicators of heart muscle damage (myocardium). They are measured in the blood to differentiate between unstable angina and myocardial infarction (heart attack) in people with chest pain or acute coronary syndrome. A person who recently had a myocardial infarction has areas of damaged heart muscle and elevated cardiac troponin levels in the blood. This can also occur in people with coronary vasospasm, a type of myocardial infarction involving severe constriction of the cardiac blood vessels. After a myocardial infarction troponins may remain high for up to 2 weeks. Cardiac troponins are a marker of all heart muscle damage, not just myocardial infarction, which is the most severe form of heart disorder. However, diagnostic criteria for raised troponin indicating myocardial infarction is currently set by the WHO at a threshold of 2 μg/L or higher. Critical levels of other cardiac biomarkers are also relevant, such as creatine kinase. Severe tachycardia (for example due to supraventricular tachycardia) in an individual with normal coronary arteries can also lead to increased troponins for example, it is presumed due to increased oxygen demand and inadequate supply to the heart muscle. Coronary artery stent placement can also cause immediate post-procedure elevated serum cardiac troponin levels. This can be problematic in a clinical setting as troponin values and guidance protocols become subject to more thoughtful interpretation.
== History == During 2008 and 2009, all non-U.S. foreign forces withdrew from Iraq. Withdrawal of all non-U.S. forces was complete by 31 July 2009. As of 1 January 2009, the Iraqi government became fully responsible, through its security ministries, for maintaining and providing security and rule of law for its populace. Furthermore, as of 28 June 2009, no foreign forces were stationed within any of Iraq's major cities. The United States decided after negotiations to cease combat operations, that is, patrolling, serving arrest warrants, route clearance, etc., within Iraq by 1 September 2010, and to transition to an advisory, training and assistance role. The changing mission entailed major troop reductions. Numbers dropped from 115,000 on 15 December 2009, to 50,000 by 1 September 2010, and to zero by 31 December 2011.
Most ants are generalist predators, scavengers, and indirect herbivores, but a few have evolved specialised ways of obtaining nutrition. It is believed that many ant species that engage in indirect herbivory rely on specialized symbiosis with their gut microbes to upgrade the nutritional value of the food they collect and allow them to survive in nitrogen poor regions, such as rainforest canopies. Leafcutter ants (Atta and Acromyrmex) feed exclusively on a fungus that grows only within their colonies. They continually collect leaves which are taken to the colony, cut into tiny pieces and placed in fungal gardens. Ergates specialise in related tasks according to their sizes. The largest ants cut stalks, smaller workers chew the leaves and the smallest tend the fungus. Leafcutter ants are sensitive enough to recognise the reaction of the fungus to different plant material, apparently detecting chemical signals from the fungus. If a particular type of leaf is found to be toxic to the fungus, the colony will no longer collect it. The ants feed on structures produced by the fungi called gongylidia. Symbiotic bacteria on the exterior surface of the ants produce antibiotics that kill bacteria introduced into the nest that may harm the fungi.
Sources: en.wikipedia.org
Acral persistent papular mucinosis Atypical lichen myxedematosus (intermediate lichen myxedematosus) Atypical tuberous myxedema (Jadassohn–Dosseker syndrome) Cutaneous focal mucinosis Cutaneous lupus mucinosis (papular and nodular mucinosis in lupus erythematosus, papular and nodular mucinosis of Gold, papulonodular mucinosis in lupus erythematosus) Discrete papular lichen myxedematosus Eccrine mucinosis Follicular mucinosis (alopecia mucinosa, mucinosis follicularis, Pinkus' follicular mucinosis, Pinkus' follicular mucinosis–benign primary form) Localized lichen myxedematosus Myxoid cyst (digital mucous cyst, mucous cyst) Myxoid lipoblastoma Neuropathia mucinosa cutanea Nodular lichen myxedematosus Papular mucinosis (generalized lichen myxedematosus, sclerodermoid lichen myxedematosus, scleromyxedema) Papular mucinosis of infancy (cutaneous mucinosis of infancy) Perifollicular mucinosis Reticular erythematous mucinosis (midline mucinosis, plaque-like cutaneous mucinosis, REM syndrome) Scleroderma Self-healing juvenile cutaneous mucinosis Self-healing papular mucinosis Stiff skin syndrome (congenital fascial dystrophy)
=== Size preferences among sexual partners === In a 1994 cover story by Psychology Today, 1,500 readers (about two-thirds women) were surveyed about male body image. Many of the women were not particularly concerned with penis size, and over 71% thought men overemphasized the importance of penis size and shape. Generally, the women polled cared more about width than men thought, and less about length than men thought, although the strength of preference for either among women showed a similar pattern. A small study of 50 undergraduate women, surveyed by two popular male athletes on campus about their perceptions of sexual satisfaction; found the width of a penis feels better than the length of a penis, when subjects are asked to choose between the two (size was left unspecified). It was also concluded that this may show that penis size overall affects sexual satisfaction, since women chose between the two options they were given. A 2002 study at Groningen University Hospital, asked 375 sexually active women (who had recently given birth) the importance of penis size. The results showed that 21% of women thought length was important and 32% thought that girth was important. A 2013 study conducted at the Australian National University, showed that penis size influences a man's sex appeal, and the taller the man, the bigger the effect. The study showed life-sized 3D computer-generated images, altering the height and other physical attributes, with women typically registering preferences in under 3 seconds. A preference for taller men's larger penis size was indicated.
=== Cycles related to the 3-hydroxypropionate cycle === A variant of the 3-hydroxypropionate cycle was found to operate in the aerobic extreme thermoacidophile archaeon Metallosphaera sedula. This pathway is called the 3-hydroxypropionate/4-hydroxybutyrate (3-HP/4-HB) cycle. Yet another variant of the 3-hydroxypropionate cycle is the dicarboxylate/4-hydroxybutyrate (DC/4-HB) cycle. It was discovered in anaerobic archaea. It was proposed in 2008 for the hyperthermophile archeon Ignicoccus hospitalis.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.